Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NBI-827104 in pediatric EECSWS
2020-003141-11Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Continuous spike and wave during slow-wave sleep (CSWS) and epileptic encephalopathy comparing NBI-827104 with Placebo (2 arms). Primary endpoint: Ratio of spike-wave index during first hour of NREM sleep. Started Dec 2020; status: completed.
02
Drugs
NBI-827104
03
Conditions
Continuous spike and wave during slow-wave sleep (CSWS)epileptic encephalopathy
Beyond the preview
Go deeper on 2020-003141-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003141-11.